Author
Peggy J. Ebner
Bio: Peggy J. Ebner is an academic researcher from University of Southern California. The author has contributed to research in topics: Odds ratio & Population. The author has an hindex of 5, co-authored 9 publications receiving 353 citations.
Papers
More filters
••
TL;DR: This population epidemiology study investigates the prevalence of IgG and IgM antibodies to SARS-CoV-2 in Los Angeles County, California, as a marker of both active and past infections.
Abstract: This population epidemiology study investigates the prevalence of IgG and IgM antibodies to SARS-CoV-2 in Los Angeles County, California, as a marker of both active and past infections.
386 citations
••
TL;DR: SES factors increase the risk of undergoing guideline discordant therapy for Stage I NSCLC, and as the number of SES factors increases, the odds of NoT rises quadratically while the chances of NST rises constantly.
30 citations
••
TL;DR: In this article, the influence of socioeconomic status (SES) on adjuvant chemotherapy after resection in patients with non-small cell lung cancer (NSCLC) was assessed.
16 citations
••
TL;DR: A literature review of 391 articles was performed to assess the current understanding of BIA‐ALCL and to provide a balanced and unbiased view of the current controversy surrounding the disease.
Abstract: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a T-cell neoplasm that arises in the capsule around breast implants. While an association with implants has been proposed, no causal link has been identified and the pathophysiology and natural history of BIA-ALCL remain unknown. A literature review of 391 articles was performed to assess the current understanding of BIA-ALCL and to provide a balanced and unbiased view of the current controversy surrounding the disease.
14 citations
••
TL;DR: Patients with SFTP who were managed with surgical intervention have better overall survival than patients who are not managed with surgery, and similar 5-year survival for sublobar resections compared with greater anatomic resections suggested that the former, when possible, is sufficient.
8 citations
Cited by
More filters
••
TL;DR: In this paper, a nationwide population-based study aims to estimate the seroprevalence of SARS-CoV-2 infection in Spain at national and regional level.
1,435 citations
18 Aug 2020
TL;DR: The majority of the Spanish population is seronegative to SARS-CoV-2 infection, even in hotspot areas, and results emphasise the need for maintaining public health measures to avoid a new epidemic wave.
749 citations
••
TL;DR: During March to early May 2020, most persons in 10 diverse geographic sites in the US had not been infected with SARS-CoV-2 virus, and the estimated number of infections was much greater than the number of reported cases in all sites.
Abstract: Importance Reported cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection likely underestimate the prevalence of infection in affected communities. Large-scale seroprevalence studies provide better estimates of the proportion of the population previously infected. Objective To estimate prevalence of SARS-CoV-2 antibodies in convenience samples from several geographic sites in the US. Design, Setting, and Participants This cross-sectional study performed serologic testing on a convenience sample of residual sera obtained from persons of all ages. The serum was collected from March 23 through May 12, 2020, for routine clinical testing by 2 commercial laboratory companies. Sites of collection were San Francisco Bay area, California; Connecticut; south Florida; Louisiana; Minneapolis-St Paul-St Cloud metro area, Minnesota; Missouri; New York City metro area, New York; Philadelphia metro area, Pennsylvania; Utah; and western Washington State. Exposures Infection with SARS-CoV-2. Main Outcomes and Measures The presence of antibodies to SARS-CoV-2 spike protein was estimated using an enzyme-linked immunosorbent assay, and estimates were standardized to the site populations by age and sex. Estimates were adjusted for test performance characteristics (96.0% sensitivity and 99.3% specificity). The number of infections in each site was estimated by extrapolating seroprevalence to site populations; estimated infections were compared with the number of reported coronavirus disease 2019 (COVID-19) cases as of last specimen collection date. Results Serum samples were tested from 16 025 persons, 8853 (55.2%) of whom were women; 1205 (7.5%) were 18 years or younger and 5845 (36.2%) were 65 years or older. Most specimens from each site had no evidence of antibodies to SARS-CoV-2. Adjusted estimates of the proportion of persons seroreactive to the SARS-CoV-2 spike protein antibodies ranged from 1.0% in the San Francisco Bay area (collected April 23-27) to 6.9% of persons in New York City (collected March 23-April 1). The estimated number of infections ranged from 6 to 24 times the number of reported cases; for 7 sites (Connecticut, Florida, Louisiana, Missouri, New York City metro area, Utah, and western Washington State), an estimated greater than 10 times more SARS-CoV-2 infections occurred than the number of reported cases. Conclusions and Relevance During March to early May 2020, most persons in 10 diverse geographic sites in the US had not been infected with SARS-CoV-2 virus. The estimated number of infections, however, was much greater than the number of reported cases in all sites. The findings may reflect the number of persons who had mild or no illness or who did not seek medical care or undergo testing but who still may have contributed to ongoing virus transmission in the population.
607 citations
••
11 Dec 2020TL;DR: This work synthesizes all known cases of true asymptomatic coronavirus disease 2019 (COVID-19) and aims to synthesize all known avian influenza A viruses to help design mitigation measures against the pandemic.
Abstract: Background: Knowing the prevalence of true asymptomatic coronavirus disease 2019 (COVID-19) cases is critical for designing mitigation measures against the pandemic. We aimed to synthesize all avai...
532 citations
••
TL;DR: Based on a systematic review and meta-analysis of published evidence on COVID-19 until July, 2020, the IFR of the disease across populations is 0.68% (0.53-0.82%).
336 citations